Eyes Down For Reckitt Benckiser Group Plc’s Results

We’ll see how Reckitt Benckiser Group Plc (LON: RB) fared in 2013.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Reckitt Benckiser Group (LSE: RB) (NASDAQOTH: RBGLY.US) shares have had a mixed ride — they’re up around 11% over 12 months to 4,656p, against a 3% rise for the FTSE 100, but it’s been a bit volatile.

The company was seen as something of a safe haven back in recession time, and its earnings were going strong — in 2009, we saw a 24% rise in earnings per share (EPS). But that growth has been slowing, down to just 7% by 2012. And analysts are actually expecting a modest fall of 1% for the year just ended in December 2013, with the same penciled in for 2014.

Results next week

Whether they’re right is something we shall find out on Wednesday 12 February, when we’ll have those 2013 results. But how has the year been going so far?

In third-quarter results released in October 2013, the owner of an array worldwide consumer brands reported like-for-like revenue growth of 5% for the quarter and the same for the year-to-date, excluding its pharmaceuticals business (RBP). Chief executive Rakesh Kapoor told us that the firm’s focus on health and hygiene and emerging markets was “delivering good results“.

And of RBP, he said “…we are commencing a strategic review of the business and will consider all options for maximising value for our shareholders. We expect the review to take some time and will update shareholders during the course of 2014“.

Prospects?

What of the full-year? Well, Mr Kapoor used that nasty “challenging” word when describing market conditions, but predicted full-year revenue growth of at least 6% with margins expected to be maintained.

Looking back further, statutory first-half EPS reported in July 2013 dropped 14% to 90.4p, though the company claimed a 7% rise to 118.3p for adjusted EPS. Like-for-like revenue at the time was up 6%, excluding RBP, with adjusted operating profit up 2% (though statutory operating profit fell 17%).

Looking at the spread of analysts’ opinions in the light of the year so far, I think Reckitt Benckiser’s 2013 EPS could be anywhere in a range of a few percent down to a few percent up.

Dividends

But what about dividends? Reckitt Benckiser traditionally provides a fairly average annual yield of a little over 3%, though it did rise a bit above that in the past couple of years as the share price fell back a little.

There’s a modest 3% rise in the 2013 dividend expected, to take it to about 138p per share for a yield of 3%. But the first-half dividend was lifted by 7% to 60p per share, so if anything that could be a bit conservative — in fact, the most recent forecasts are suggesting around 140p per share.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares in Reckitt Benckiser.

More on Investing Articles

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Down 21% and yielding 10%, is this income stock a top contrarian buy now?

Despite its falling share price, this Fool reckons he's found an income stock that could be worth taking a closer…

Read more »

Investing Articles

The Meta share price falls 10% on weak Q2 guidance — should investors consider buying?

The Meta Platforms' share price is down 10% after the company reported Q1 earnings per share growth of 117%. Does…

Read more »